Clinical Trials · NCT06700538
A First-In-Human Study of ARO-INHBE in Adults With Obesity With and Without Type 2 Diabetes Mellitus
- Phase
- Phase 1/Phase 2
- Recruitment status
- Recruiting
- Sponsor
- Arrowhead Pharmaceuticals
- Enrollment
- 180
- Start date
- Dec 2024
- Locations
- 5 sites, New Zealand
- Primary endpoint
- Number of Participants with Treatment-Emergent Adverse Events (TEAEs)